Acasti Pharma Inc (ACST.OQ) Key Developments | Reuters.com
Edition:
United States

Acasti Pharma Inc (ACST.OQ)

ACST.OQ on NASDAQ Stock Exchange Capital Market

1.55USD
24 Jun 2016
Change (% chg)

-- (--)
Prev Close
$1.55
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,039
52-wk High
$4.20
52-wk Low
$1.20

Latest Key Developments (Source: Significant Developments)

Acasti Pharma says Jan D'Alvise named as CEO
Thursday, 12 May 2016 08:08am EDT 

Acasti Pharma Inc : Says Jan D'Alvise appointed as president and chief executive officer effective June 1, 2016 .Jan D'Alvise appointed president & CEO of Acasti Pharma.  Full Article

Acasti Pharma Inc says appointment of Roderick Carter, as Executive Chairman of the Board
Tuesday, 1 Mar 2016 08:00am EST 

Acasti Pharma Inc:Says appointment of Roderick Carter, as Executive Chairman of the Board.  Full Article

Acasti Pharma Inc announces departure of chief financial officer
Wednesday, 29 Apr 2015 06:35pm EDT 

Acasti Pharma Inc:Says departure of andré godin as chief financial officer effective immediately.  Full Article

Acasti Pharma Inc announces positive top-line pharmacokinetic results
Tuesday, 30 Sep 2014 08:00am EDT 

Acasti Pharma Inc:Announces top-line results for its pharmacokinetic trial evaluating the bioavailability and safety of CaPre on healthy individuals taking single and multiple daily oral doses of the Corporation's new investigational drug candidate.Says it composed of a patent-protected highly concentrated novel omega-3 phospholipid for the prevention and treatment of certain cardiometabolic disorders.  Full Article

Acasti Pharma Inc announces appointment of Chairman
Tuesday, 15 Jul 2014 05:48pm EDT 

Acasti Pharma Inc:Says, at Acasti's Annual & Special Meeting, held on June 19, 2014, shareholders elected slate of directors.Following vote at Board meeting held on July 15, 2014, Jerald J. Wenker was appointed Chairman of Board of Acasti, effective immediately.  Full Article

Acasti Pharma Inc completes phase II Double Blind (TRIFECTA) and Pharmacokinetic Trials
Wednesday, 9 Jul 2014 08:00am EDT 

Acasti Pharma Inc:Completion of two trials, the Phase II double-blind, placebo-controlled (TRIFECTA) study and the Pharmacokinetic (PK) trial.Says results of the Phase II and PK trials are important part of Acasti's on-going discussions with US Food and Drug Administration (FDA) to obtain approval to conduct Phase III trial in the USA.Says primary objective of the TRIFECTA trial is to evaluate the safety and efficacy of CaPre in reducing triglyceride levels in patients with mild to severe hypertriglyceridemia.Upon reaching the number of targeted patients, a planned second blinded interim analysis indicated a significant clinical signal, without any safety concerns.Says given that stopping threshold had been met, the data review committee members recommended that there was sufficient evidence of a treatment effect that warranted the termination of the study.Intends to unblind study and top-line results are expected by end of September with full data coming out in the following quarter.Acasti's Pharmacokinetic trial is designed to evaluate blood profiles and bioavailability in healthy human volunteers taking single and multiple doses of Capre.  Full Article

BRIEF-TomaGold buys Obalski property

* Signed an agreement to acquire Obalski property from David Malouf and 2736-1179 Quebec Inc